Responses
Clinical and epidemiological research
Extended report
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations
Compose a Response to This Article
Other responses
No responses have been published for this article.